<VariationArchive VariationID="6940" VariationName="NM_002485.5(NBN):c.657_661del (p.Lys219fs)" VariationType="Deletion" Accession="VCV000006940" Version="92" RecordType="classified" NumberOfSubmissions="44" NumberOfSubmitters="38" DateLastUpdated="2024-07-29" DateCreated="2015-10-05" MostRecentSubmission="2024-07-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="21979" VariationID="6940">
      <GeneList>
        <Gene Symbol="NBN" FullName="nibrin" GeneID="4683" HGNC_ID="HGNC:7652" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>8q21.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="8" Accession="NC_000008.11" start="89933331" stop="89984667" display_start="89933331" display_stop="89984667" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="8" Accession="NC_000008.10" start="90945563" stop="90996898" display_start="90945563" display_stop="90996898" Strand="-" />
          </Location>
          <OMIM>602667</OMIM>
          <Haploinsufficiency last_evaluated="2020-08-21" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=NBN">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-08-21" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=NBN">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_002485.5(NBN):c.657_661del (p.Lys219fs)</Name>
      <CanonicalSPDI>NC_000008.11:89971213:TTTGTTTT:TTT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>8q21.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="8" Accession="NC_000008.11" start="89971214" stop="89971218" display_start="89971214" display_stop="89971218" variantLength="5" positionVCF="89971213" referenceAlleleVCF="ATTTGT" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="8" Accession="NC_000008.10" start="90983442" stop="90983446" display_start="90983442" display_stop="90983446" variantLength="5" positionVCF="90983441" referenceAlleleVCF="ATTTGT" alternateAlleleVCF="A" />
      </Location>
      <OtherNameList>
        <Name>657del5</Name>
      </OtherNameList>
      <ProteinChange>K137fs</ProteinChange>
      <ProteinChange>K219fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000008.10" sequenceAccession="NC_000008" sequenceVersion="10" change="g.90983445_90983449del" Assembly="GRCh37">
            <Expression>NC_000008.10:g.90983445_90983449del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000008.11" sequenceAccession="NC_000008" sequenceVersion="11" change="g.89971217_89971221del" Assembly="GRCh38">
            <Expression>NC_000008.11:g.89971217_89971221del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008860.1" sequenceAccession="NG_008860" sequenceVersion="1" change="g.18454_18458del">
            <Expression>NG_008860.1:g.18454_18458del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001024688.3" sequenceAccession="NM_001024688" sequenceVersion="3" change="c.411_415del">
            <Expression>NM_001024688.3:c.411_415del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001019859.1" sequenceAccession="NP_001019859" sequenceVersion="1" change="p.Lys137fs">
            <Expression>NP_001019859.1:p.Lys137fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_002485.5" sequenceAccession="NM_002485" sequenceVersion="5" change="c.657_661del" MANESelect="true">
            <Expression>NM_002485.5:c.657_661del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_002476.2" sequenceAccession="NP_002476" sequenceVersion="2" change="p.Lys219fs">
            <Expression>NP_002476.2:p.Lys219fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_158" sequenceAccession="LRG_158">
            <Expression>LRG_158:g.18454_18458del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_002485.5" sequenceAccession="NM_002485" sequenceVersion="5" change="c.657_661delACAAA" MANESelect="true">
            <Expression>NM_002485.5:c.657_661delACAAA</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_002485.4" sequenceAccession="NM_002485" sequenceVersion="4" change="c.657_661delACAAA">
            <Expression>NM_002485.4:c.657_661delACAAA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA254009" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="602667.0001" DB="OMIM" />
        <XRef Type="rs" ID="587776650" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_002485.5(NBN):c.657_661del (p.Lys219fs) AND Breast-ovarian cancer, familial, susceptibility to, 1" Accession="RCV000007354" Version="13">
        <ClassifiedConditionList TraitSetID="1917">
          <ClassifiedCondition DB="MedGen" ID="C2676676">Breast-ovarian cancer, familial, susceptibility to, 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-04-02" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002485.5(NBN):c.657_661del (p.Lys219fs) AND Microcephaly, normal intelligence and immunodeficiency" Accession="RCV000007353" Version="52">
        <ClassifiedConditionList TraitSetID="1916">
          <ClassifiedCondition DB="MedGen" ID="C0398791">Microcephaly, normal intelligence and immunodeficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-02-01" SubmissionCount="20">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002485.5(NBN):c.657_661del (p.Lys219fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV000133576" Version="31">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2021-08-13" SubmissionCount="6">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002485.5(NBN):c.657_661del (p.Lys219fs) AND not provided" Accession="RCV000212733" Version="55">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-05-01" SubmissionCount="7">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002485.5(NBN):c.657_661del (p.Lys219fs) AND multiple conditions" Accession="RCV000415248" Version="10">
        <ClassifiedConditionList TraitSetID="17516">
          <ClassifiedCondition DB="MedGen" ID="C0266463">Lissencephaly</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C4551563">Microcephaly</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2015-10-06" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002485.5(NBN):c.657_661del (p.Lys219fs) AND multiple conditions" Accession="RCV001535498" Version="10">
        <ClassifiedConditionList TraitSetID="68191">
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0398791">Microcephaly, normal intelligence and immunodeficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no classification provided</ReviewStatus>
            <Description SubmissionCount="1">not provided</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002485.5(NBN):c.657_661del (p.Lys219fs) AND Carcinoma of pancreas" Accession="RCV001391203" Version="9">
        <ClassifiedConditionList TraitSetID="6482">
          <ClassifiedCondition DB="MedGen" ID="C0235974">Carcinoma of pancreas</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2021-03-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002485.5(NBN):c.657_661del (p.Lys219fs) AND Breast carcinoma" Accession="RCV001574072" Version="9">
        <ClassifiedConditionList TraitSetID="17313">
          <ClassifiedCondition DB="MedGen" ID="C0678222">Breast carcinoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2021-08-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002485.5(NBN):c.657_661del (p.Lys219fs) AND Breast and/or ovarian cancer" Accession="RCV001270991" Version="9">
        <ClassifiedConditionList TraitSetID="20192">
          <ClassifiedCondition DB="MedGen" ID="CN221562">Breast and/or ovarian cancer</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2019-06-11" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002485.5(NBN):c.657_661del (p.Lys219fs) AND Malignant tumor of breast" Accession="RCV001357671" Version="10">
        <ClassifiedConditionList TraitSetID="25616">
          <ClassifiedCondition DB="MedGen" ID="C0006142">Malignant tumor of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002485.5(NBN):c.657_661del (p.Lys219fs) AND Hepatocellular carcinoma" Accession="RCV002280859" Version="8">
        <ClassifiedConditionList TraitSetID="6315">
          <ClassifiedCondition DB="MedGen" ID="C2239176">Hepatocellular carcinoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2022-05-17" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002485.5(NBN):c.657_661del (p.Lys219fs) AND NBN-related disorder" Accession="RCV003389666" Version="4">
        <ClassifiedConditionList TraitSetID="89281">
          <ClassifiedCondition>NBN-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-03-03" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002485.5(NBN):c.657_661del (p.Lys219fs) AND Aplastic anemia" Accession="RCV003460432" Version="2">
        <ClassifiedConditionList TraitSetID="1918">
          <ClassifiedCondition DB="MedGen" ID="C0002874">Aplastic anemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-03-27" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-05-01" NumberOfSubmissions="44" NumberOfSubmitters="38" DateCreated="2015-10-05" MostRecentSubmission="2024-07-15">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16033915</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16544999</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17103455</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18606567</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18940477</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19635536</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19908051</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20444919</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22131123</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22293976</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22373003</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22491912</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23317186</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24113799</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25485873</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25980754</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26083025</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26822949</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27150568</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27616075</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28873162</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29368341</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29419426</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30426508</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31173646</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33050356</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33471974</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33471991</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33840814</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34072463</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34072659</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34544220</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">35309086</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9590180</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9590181</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9620777</ID>
        </Citation>
        <Citation Type="review" Abbrev="GeneReviews">
          <ID Source="PubMed">20301355</ID>
          <ID Source="BookShelf">NBK1176</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">10398434</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">10799436</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">10848790</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">10852373</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11093281</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11279524</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11953735</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12123493</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12505263</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12833396</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12845677</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">14973119</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15185344</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15279809</ID>
        </Citation>
        <DescriptionHistory Dated="2024-02-08">
          <Description>Conflicting classifications of pathogenicity</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2023-11-19">
          <Description>Conflicting classifications of pathogenicity; risk factor</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2022-03-16">
          <Description>Conflicting classifications of pathogenicity, risk factor</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2021-03-07">
          <Description>Pathogenic, risk factor</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2020-07-03">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2018-05-29">
          <Description>Pathogenic, risk factor</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="1916" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3184" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">IMMUNODEFICIENCY, MICROCEPHALY, AND CHROMOSOMAL INSTABILITY</ElementValue>
                <XRef Type="MIM" ID="251260" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Nijmegen breakage syndrome</ElementValue>
                <XRef ID="MONDO:0009623" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Microcephaly, normal intelligence and immunodeficiency</ElementValue>
                <XRef ID="Microcephaly+with+normal+intelligence%2C+immunodeficiency/4760" DB="Genetic Alliance" />
                <XRef ID="234638009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Immunodeficiency, microcephaly with normal intelligence</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">SEEMANOVA SYNDROME II</ElementValue>
                <XRef Type="MIM" ID="251260" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ataxia telangiectasia variant V1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Berlin Breakage syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Microcephaly with normal intelligence immunodeficiency and lymphoreticular malignancies</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Nonsyndromal microcephaly autosomal recessive with normal intelligence</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Seemanova syndrome 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">NBS</ElementValue>
                <XRef Type="MIM" ID="251260" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">BBS</ElementValue>
                <XRef ID="251260" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">AT-V1</ElementValue>
                <XRef Type="MIM" ID="251260" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3904" />
                <XRef ID="3904" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Nijmegen breakage syndrome (NBS) is characterized by progressive microcephaly, early growth deficiency that improves with age, recurrent respiratory infections, an increased risk for malignancy (primarily lymphoma), and premature ovarian failure in females. Developmental milestones are attained at the usual time during the first year; however, borderline delays in development and hyperactivity may be observed in early childhood. Intellectual abilities tend to decline over time. Recurrent pneumonia and bronchitis may result in respiratory failure and early death. Other reported malignancies include solid tumors (e.g., medulloblastoma, glioma, rhabdomyosarcoma).</Attribute>
                <XRef ID="NBK1176" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301355</ID>
                <ID Source="BookShelf">NBK1176</ID>
              </Citation>
              <XRef ID="647" DB="Orphanet" />
              <XRef ID="C0398791" DB="MedGen" />
              <XRef ID="MONDO:0009623" DB="MONDO" />
              <XRef Type="MIM" ID="251260" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="20192" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="32337" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Breast and/or ovarian cancer</ElementValue>
                <XRef ID="UWMG_7622958" DB="CSER _CC_NCGL, University of Washington" />
              </Name>
              <XRef ID="CN221562" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="89281" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="70929" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">NBN-related disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">NBN-related condition</ElementValue>
              </Name>
            </Trait>
          </TraitSet>
          <TraitSet ID="25616" Type="Finding" ContributesToAggregateClassification="false">
            <Trait ID="34847" Type="Finding">
              <Name>
                <ElementValue Type="Preferred">Malignant tumor of breast</ElementValue>
                <XRef ID="254837009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Malignant breast neoplasm</ElementValue>
                <XRef ID="C9335" DB="NCI" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer breast</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="pmc">2936467</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2018">
                <ID Source="PubMed">29939840</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479144</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2019">
                <ID Source="PubMed">30452337</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2018">
                <URL>https://www.nice.org.uk/guidance/dg34</URL>
                <CitationText>Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/ng12</URL>
                <CitationText>UK NICE Guideline NG12, Suspected cancer: recognition and referral, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="C0006142" DB="MedGen" />
              <XRef ID="MONDO:0007254" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="68191" Type="TraitChoice" ContributesToAggregateClassification="false">
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17142" />
                <XRef ID="17142" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
            <Trait ID="3184" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">IMMUNODEFICIENCY, MICROCEPHALY, AND CHROMOSOMAL INSTABILITY</ElementValue>
                <XRef Type="MIM" ID="251260" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Nijmegen breakage syndrome</ElementValue>
                <XRef ID="MONDO:0009623" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Microcephaly, normal intelligence and immunodeficiency</ElementValue>
                <XRef ID="Microcephaly+with+normal+intelligence%2C+immunodeficiency/4760" DB="Genetic Alliance" />
                <XRef ID="234638009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Immunodeficiency, microcephaly with normal intelligence</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">SEEMANOVA SYNDROME II</ElementValue>
                <XRef Type="MIM" ID="251260" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ataxia telangiectasia variant V1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Berlin Breakage syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Microcephaly with normal intelligence immunodeficiency and lymphoreticular malignancies</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Nonsyndromal microcephaly autosomal recessive with normal intelligence</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Seemanova syndrome 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">NBS</ElementValue>
                <XRef Type="MIM" ID="251260" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">BBS</ElementValue>
                <XRef ID="251260" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">AT-V1</ElementValue>
                <XRef Type="MIM" ID="251260" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3904" />
                <XRef ID="3904" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Nijmegen breakage syndrome (NBS) is characterized by progressive microcephaly, early growth deficiency that improves with age, recurrent respiratory infections, an increased risk for malignancy (primarily lymphoma), and premature ovarian failure in females. Developmental milestones are attained at the usual time during the first year; however, borderline delays in development and hyperactivity may be observed in early childhood. Intellectual abilities tend to decline over time. Recurrent pneumonia and bronchitis may result in respiratory failure and early death. Other reported malignancies include solid tumors (e.g., medulloblastoma, glioma, rhabdomyosarcoma).</Attribute>
                <XRef ID="NBK1176" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301355</ID>
                <ID Source="BookShelf">NBK1176</ID>
              </Citation>
              <XRef ID="647" DB="Orphanet" />
              <XRef ID="C0398791" DB="MedGen" />
              <XRef ID="MONDO:0009623" DB="MONDO" />
              <XRef Type="MIM" ID="251260" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6482" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="5725" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Carcinoma of pancreas</ElementValue>
                <XRef ID="372142002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PANCREATIC ACINAR CARCINOMA</ElementValue>
                <XRef Type="MIM" ID="260350" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PANCREATIC CARCINOMA</ElementValue>
                <XRef Type="MIM" ID="260350" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pancreatic cancer, somatic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Exocrine pancreatic carcinoma</ElementValue>
                <XRef ID="MONDO:0005192" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pancreatic carcinoma, somatic</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000593405" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569885" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512726" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000012368" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520869" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520872" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592353" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520069" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000523334" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000593406" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520871" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520865" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000523331" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000525919" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569881" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592354" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514885" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000523332" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528055" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520866" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552440" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520870" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520868" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000597429" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509790" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000593404" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="AHRQ, 2013">
                <URL>https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id90TA.pdf</URL>
                <CitationText>Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin (ARCHIVED)</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2006">
                <ID Source="PubMed">17060676</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="1333" DB="Orphanet" />
              <XRef ID="217074" DB="Orphanet" />
              <XRef ID="C0235974" DB="MedGen" />
              <XRef ID="C562463" DB="MeSH" />
              <XRef ID="MONDO:0005192" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6315" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="18496" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hepatocellular carcinoma</ElementValue>
                <XRef ID="HP:0001402" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0007256" DB="MONDO" />
                <XRef ID="25370001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Primary carcinoma of liver</ElementValue>
                <XRef ID="187769009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hepatoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">LIVER CELL CARCINOMA</ElementValue>
                <XRef Type="MIM" ID="114550" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hepatocellular cancer</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">HCC</ElementValue>
                <XRef Type="MIM" ID="114550" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">LCC</ElementValue>
                <XRef Type="MIM" ID="114550" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="16773" />
                <XRef ID="16773" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Hepatocellular Carcinoma, 2024</CitationText>
              </Citation>
              <XRef ID="88673" DB="Orphanet" />
              <XRef ID="C2239176" DB="MedGen" />
              <XRef ID="MONDO:0007256" DB="MONDO" />
              <XRef Type="MIM" ID="114550" DB="OMIM" />
              <XRef Type="primary" ID="HP:0001402" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0002899" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0003007" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0006750" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="17516" Type="Finding" ContributesToAggregateClassification="true">
            <Trait ID="21539" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Microcephaly (disease)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Microcephaly</ElementValue>
                <XRef ID="HP:0000252" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0001149" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3603" />
                <XRef ID="3603" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="Retired, AAN/CNS, 2009">
                <ID Source="pmc">2744281</ID>
              </Citation>
              <XRef ID="C4551563" DB="MedGen" />
              <XRef ID="MONDO:0001149" DB="MONDO" />
              <XRef Type="primary" ID="HP:0000252" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0001366" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0005485" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0005489" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0005497" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="16724" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Lissencephaly</ElementValue>
                <XRef ID="HP:0001339" DB="Human Phenotype Ontology" />
                <XRef Type="Phenotypic series" ID="PS607432" DB="OMIM" />
                <XRef ID="204036008" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lissencephaly spectrum disorders</ElementValue>
                <XRef ID="MONDO:0018838" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12291" />
                <XRef ID="12291" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="48471" DB="Orphanet" />
              <XRef ID="C0266463" DB="MedGen" />
              <XRef ID="D054082" DB="MeSH" />
              <XRef ID="MONDO:0018838" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS607432" DB="OMIM" />
              <XRef Type="primary" ID="HP:0001339" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0002537" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="17313" Type="Finding" ContributesToAggregateClassification="false">
            <Trait ID="23475" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Breast carcinoma</ElementValue>
                <XRef ID="HP:0003002" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0004989" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carcinoma of breast</ElementValue>
                <XRef ID="254838004" DB="SNOMED CT" />
              </Name>
              <XRef ID="C0678222" DB="MedGen" />
              <XRef ID="MONDO:0004989" DB="MONDO" />
              <XRef Type="primary" ID="HP:0003002" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1917" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4711" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Breast-ovarian cancer, familial 1</ElementValue>
                <XRef ID="Breast-ovarian+cancer%2C+familial+1/7865" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">OVARIAN CANCER, SUSCEPTIBILITY TO</ElementValue>
                <XRef Type="Allelic variant" ID="602667.0001" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Breast-ovarian cancer, familial, susceptibility to, 1</ElementValue>
                <XRef ID="MONDO:0011450" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">BROVCA1</ElementValue>
                <XRef Type="MIM" ID="604370" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000332529" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507653" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021517" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501743" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514601" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000330054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017876" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520866" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512816" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501746" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509002" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520865" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509982" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512320" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551440" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552304" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509983" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519030" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531275" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520871" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569406" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000320777" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520870" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522161" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520071" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507764" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522159" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509980" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512645" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507864" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520072" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521908" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501817" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509001" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520069" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325409" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520872" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520869" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509692" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592961" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12351" />
                <XRef ID="12351" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19305347</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Phillips et al., 2013">
                <ID Source="PubMed">23918944</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Domchek et al., 2010">
                <ID Source="pmc">2948529</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, 2024</CitationText>
              </Citation>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C2676676" DB="MedGen" />
              <XRef ID="MONDO:0011450" DB="MONDO" />
              <XRef Type="MIM" ID="604370" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1918" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4604" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Aplastic anemia</ElementValue>
                <XRef ID="Aplastic+Anemia/556" DB="Genetic Alliance" />
                <XRef ID="HP:0001915" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0015909" DB="MONDO" />
                <XRef ID="306058006" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="20234" />
                <XRef ID="20234" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="182040" DB="Orphanet" />
              <XRef ID="88" DB="Orphanet" />
              <XRef ID="C0002874" DB="MedGen" />
              <XRef ID="MONDO:0015909" DB="MONDO" />
              <XRef Type="MIM" ID="609135" DB="OMIM" />
              <XRef Type="primary" ID="HP:0001915" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="459776" SubmissionDate="2015-09-15" DateLastUpdated="2015-10-05" DateCreated="2015-10-05">
        <ClinVarSubmissionID localKey="NM_002485.4(NBN):c.657_661del|Nijmegen breakage syndrome" />
        <ClinVarAccession Accession="SCV000248141" DateUpdated="2015-10-05" DateCreated="2015-10-05" Type="SCV" Version="1" SubmitterName="Genetic Services Laboratory, University of Chicago" OrgID="1238" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-03-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Nijmegen breakage syndrome</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="480833" SubmissionDate="2015-11-24" DateLastUpdated="2015-10-11" DateCreated="2015-10-11">
        <ClinVarSubmissionID localKey="SUB1187971" title="SUB1187971" />
        <ClinVarAccession Accession="SCV000256868" DateUpdated="2015-10-11" DateCreated="2015-10-11" Type="SCV" Version="1" SubmitterName="Miami Human Genetics, University Of Miami Miller School Of Medicine" OrgID="505599" OrganizationCategory="laboratory" OrgAbbreviation="MHG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-11-16">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Type="general">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <TypePlatform>Next-generation exome sequencing</TypePlatform>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="Human Phenotype Ontology" ID="HP:0000252" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="Human Phenotype Ontology" ID="HP:0003220" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="Human Phenotype Ontology" ID="HP:0001249" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBS1">
              <Name>nibrin</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661delACAAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251260" />
          </Trait>
        </TraitSet>
        <StudyName>Miami Human Genetics</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB1187971</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="498393" SubmissionDate="2016-03-03" DateLastUpdated="2016-03-20" DateCreated="2016-03-20">
        <ClinVarSubmissionID localKey="c.657_661delACAAA" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000266100" DateUpdated="2016-03-20" DateCreated="2016-03-20" Type="SCV" Version="1" SubmitterName="University of Washington Department of Laboratory Medicine, University of Washington" OrgID="506834" OrganizationCategory="laboratory" OrgAbbreviation="UWLABMED" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-11-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Shirts et al. (Genet Med 2016)</Attribute>
          <Citation>
            <ID Source="PubMed">26845104</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">50</Age>
              <Age Type="maximum" age_unit="years">59</Age>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SampleLocalID">902</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <Name>
                  <ElementValue Type="Preferred">breast cancer</ElementValue>
                </Name>
              </Trait>
            </TraitSet>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">50</Age>
              <Age Type="maximum" age_unit="years">59</Age>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SampleLocalID">1616</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <Name>
                  <ElementValue Type="Preferred">ovarian cancer</ElementValue>
                </Name>
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <Name>
                  <ElementValue Type="Preferred">endometrial cancer</ElementValue>
                </Name>
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661delACAAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GIM_BROCA</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="962427" SubmissionDate="2016-11-12" DateLastUpdated="2017-01-13" DateCreated="2017-01-13">
        <ClinVarSubmissionID localKey="CMGVARID00342|HPO:HP:0001339;HP:0000252" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000492771" DateUpdated="2017-01-13" DateCreated="2017-01-13" Type="SCV" Version="1" SubmitterName="Centre for Mendelian Genomics, University Medical Centre Ljubljana" OrgID="505952" OrganizationCategory="clinic" OrgAbbreviation="CMG-UMCL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-10-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661delACAAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Finding">
          <Trait Type="Finding">
            <XRef DB="HP" ID="HP:0001339" />
          </Trait>
          <Trait Type="Finding">
            <XRef DB="HP" ID="HP:0000252" />
          </Trait>
        </TraitSet>
        <StudyDescription>Diagnostic exome sequencing variant classification from diagnostic exome sequencing programme</StudyDescription>
        <SubmissionNameList>
          <SubmissionName>CMG_Slovenia_Submission_1</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2292638" SubmissionDate="2019-09-27" DateLastUpdated="2020-02-28" DateCreated="2020-02-28">
        <ClinVarSubmissionID localKey="NC_000008.10:g.90983445_90983449delGTTTT|OMIM:251260" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001163582" DateUpdated="2020-02-28" DateCreated="2020-02-28" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000008.10:g.90983445_90983449delGTTTT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251260" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>BG_GA_2018_SNVs_INDELS</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2693660" SubmissionDate="2020-05-14" DateLastUpdated="2020-07-04" DateCreated="2020-07-04">
        <ClinVarSubmissionID localKey="97629026|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001365763" DateUpdated="2020-07-04" DateCreated="2020-07-04" Type="SCV" Version="1" SubmitterName="Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine" OrgID="21766" OrganizationCategory="laboratory" OrgAbbreviation="LMM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-05-08">
          <ReviewStatus>flagged submission</ReviewStatus>
          <GermlineClassification>risk factor</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24113799</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11279524</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9590180</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22131123</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23317186</ID>
          </Citation>
          <Comment>The p.Lys219AsnfsX16 variant in NBN is associated with an increased risk for NBN-related cancers (Gao 2013, Zhang 2012). Large meta-analyses have reported significant odds ratios in carriers of the variant for multiple cancers, particularly breast cancer (OR = 2.63 [95% CI=1.76-3.93]), prostate cancer (OR = 5.87 [95% CI=2.51-13.75]), and lymphoma (OR = 2.93 [95% CI=1.62-5.29]) (Gao 2013, Zhang 2012). Additionally, in the bi-allelic state, this variant is the most common variant associated with autosomal recessive Nijmegen Breakage Syndrome (NBS). It has also been identified in 52/128774 European chromosomes by gnomAD (http://gnomad.broadinstitute.org). This variant has also been reported in ClinVar (Variation ID: 6940). This variant is predicted to cause a frameshift, which alters the proteinâ€™s amino acid sequence beginning at position 219 and leads to a premature termination codon 16 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the NBN gene is an established disease mechanism in autosomal recessive NBS. In vitro functional studies support an impact on protein function and show that this variant leads to the production of an abnormal protein product (Maser 2001, Dzikiewicz-Krawczyk 2012). In summary, this variant meets criteria to be classified as an established risk allele for breast, prostate, and lymphoid cancers.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LMM Criteria</Attribute>
          <Citation>
            <ID Source="PubMed">24033266</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="1" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000008.10:g.90983442_90983446delTTTGT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <Comment DataSource="NCBI" Type="FlaggedComment">Reason: This record appears to be redundant with a more recent record from the same submitter.</Comment>
        <Comment DataSource="NCBI" Type="FlaggedComment">Notes: SCV001365763 appears to be redundant with SCV001365920.</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB7448406</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2693817" SubmissionDate="2020-05-14" DateLastUpdated="2020-07-04" DateCreated="2020-07-04">
        <ClinVarSubmissionID localKey="97629026|Orphanet:ORPHA647" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001365920" DateUpdated="2020-07-04" DateCreated="2020-07-04" Type="SCV" Version="1" SubmitterName="Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine" OrgID="21766" OrganizationCategory="laboratory" OrgAbbreviation="LMM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-05-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24113799</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11279524</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9590180</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22131123</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23317186</ID>
          </Citation>
          <Comment>The p.Lys219AsnfsX16 variant in NBN is the most common NBN variant associated with autosomal recessive Nijmegen Breakage Syndrome (NBS) and has been reported as a founder variant in Slavic populations (Varon 1998). Additionally, in the heterozygous state, this variant has been found to increase risk to certain NBS-related cancers (Gao 2013, Zhang 2012). It has also been identified in 52/128774 European chromosomes by gnomAD (http://gnomad.broadinstitute.org). However, this frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID: 6940). This variant is predicted to cause a frameshift, which alters the proteinâ€™s amino acid sequence beginning at position 219 and leads to a premature termination codon 16 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the NBN gene is an established disease mechanism in autosomal recessive NBS. In vitro functional studies support an impact on protein function and show that this variant leads to the production of an abnormal protein product (Maser 2001, Dzikiewicz-Krawczyk 2012). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive NBS. ACMG/AMP criteria applied: PVS1, PM3_VeryStrong, PS3_Supporting.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LMM Criteria</Attribute>
          <Citation>
            <ID Source="PubMed">24033266</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="1" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000008.10:g.90983442_90983446delTTTGT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA647" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB7448406</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2861309" SubmissionDate="2020-09-02" DateLastUpdated="2020-12-12" DateCreated="2020-12-12">
        <ClinVarSubmissionID localKey="1258964|Hereditary cancer-predisposing syndrome" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001449031" DateUpdated="2020-12-12" DateCreated="2020-12-12" Type="SCV" Version="1" SubmitterName="Knight Diagnostic Laboratories, Oregon Health and Sciences University" OrgID="505542" OrganizationCategory="laboratory" OrgAbbreviation="KDL-OHSU" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-05-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
              <MethodAttribute>
                <Attribute Type="TestName">Healthy Oregon Project</Attribute>
              </MethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="2" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="8" alternateAllele="A" referenceAllele="ATTTGT" start="90983441" stop="90983446" variantLength="6" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB7918263</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2694238" SubmissionDate="2020-11-24" DateLastUpdated="2020-12-12" DateCreated="2020-07-04">
        <ClinVarSubmissionID localKey="NM_002485.4:c.657_661delACAAA|OMIM:251260" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001366157" DateUpdated="2020-12-12" DateCreated="2020-07-04" Type="SCV" Version="2" SubmitterName="Centre for Mendelian Genomics, University Medical Centre Ljubljana" OrgID="505952" OrganizationCategory="clinic" OrgAbbreviation="CMG-UMCL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-10-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PS1,PM2.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661delACAAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251260" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8622351</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2866888" SubmissionDate="2019-06-13" DateLastUpdated="2020-12-24" DateCreated="2020-12-24">
        <ClinVarSubmissionID localKey="NM_002485.4:c.657_661del|MedGen:CN221562" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001451803" DateUpdated="2020-12-24" DateCreated="2020-12-24" Type="SCV" Version="1" SubmitterName="CZECANCA consortium" OrgID="507065" OrganizationCategory="consortium" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-06-11">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Slavic</Ethnicity>
              <GeographicOrigin>Czech Republic</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>case-control</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Slavic</Ethnicity>
              <GeographicOrigin>Czech Republic</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="12" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Breast and/or ovarian cancer</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="CN221562" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">32295079</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB5822876</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3134890" SubmissionDate="2021-05-11" DateLastUpdated="2021-05-14" DateCreated="2021-05-14">
        <ClinVarSubmissionID localKey="NM_002485.4:c.657_661del|MedGen:C0235974" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001593146" DateUpdated="2021-05-14" DateCreated="2021-05-14" Type="SCV" Version="1" SubmitterName="CZECANCA consortium" OrgID="507065" OrganizationCategory="consortium" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-03-04">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Slavic</Ethnicity>
              <GeographicOrigin>Czech Republic</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="3" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0235974" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9610848</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1609811" SubmissionDate="2021-09-29" DateLastUpdated="2021-10-02" DateCreated="2018-10-10">
        <ClinVarSubmissionID localKey="NM_002485.4:c.657_661delACAAA|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000821748" DateUpdated="2021-10-02" DateCreated="2018-10-10" Type="SCV" Version="3" SubmitterName="GeneKor MSA" OrgID="505504" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-01-09">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This is a deletion of five base pairs from exon 6 of the NBN mRNA (c.657_661delACAAA), which results in frameshift after codon 219 and creation of a novel stop codon 16 amino acid residues later and would generally be expected to result in an absent or disrupted protein product.This is the most common variant reported in individuals affected with Nijmegen breakage syndrome (NBS), and is considered to be a founder mutation in the Slavic population (PMID: 9590180). It is also known as 657del5 in the literature. Heterozygous carriers may have increased risk for several types of cancers including breast, lymphoma, melanoma, medulloblastoma, prostate and others (PMID: 15185344, 14973119, 18606567, 19908051, 24113799). Experimental studies propose that this deletion encodes a partially functional protein that diminishes the severity of the NBS phenotype (PMID: 11279524). The mutation database Clinvar contains entries for this variant (Variation ID:6940).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661delACAAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10447902</SubmissionName>
          <SubmissionName>SUB6775616</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4011513" SubmissionDate="2021-12-29" DateLastUpdated="2022-01-03" DateCreated="2022-01-03">
        <ClinVarSubmissionID localKey="NM_002485.5:c.657_661del|OMIM:251260" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002045955" DateUpdated="2022-01-03" DateCreated="2022-01-03" Type="SCV" Version="1" SubmitterName="Genome-Nilou Lab" OrgID="507598" OrganizationCategory="laboratory" OrgAbbreviation="Genome Nilou" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.5:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251260" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10872261</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5024075" SubmissionDate="2022-09-01" DateLastUpdated="2022-09-10" DateCreated="2022-09-10">
        <ClinVarSubmissionID localKey="NM_002485.5:c.657_661del|OMIM:114550" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002569170" DateUpdated="2022-09-10" DateCreated="2022-09-10" Type="SCV" Version="1" SubmitterName="CZECANCA consortium" OrgID="507065" OrganizationCategory="consortium" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-17">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>case-control</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.5:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114550" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11993892</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5030686" SubmissionDate="2022-09-04" DateLastUpdated="2022-09-17" DateCreated="2022-09-17">
        <ClinVarSubmissionID localKey="8-90983441-ATTTGT-A" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002573068" DateUpdated="2022-09-17" DateCreated="2022-09-17" Type="SCV" Version="1" SubmitterName="3billion" OrgID="507830" OrganizationCategory="other" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-09-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9590180</ID>
          </Citation>
          <Comment>The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.020%). It is predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported at least twice as pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000006940 / PMID: 9590180). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Proband>yes</Proband>
            </Sample>
            <Method>
              <NamePlatform>NovaSeq</NamePlatform>
              <TypePlatform>whole exome sequencing</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Homozygote" integerValue="1" />
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0000252" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001511" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001629" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0000126" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0000750" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001510" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.5:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251260" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12013725</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="967778" SubmissionDate="2017-02-02" DateLastUpdated="2022-10-01" DateCreated="2016-07-01">
        <ClinVarSubmissionID localKey="NM_002485.4:c.657_661del5|OMIM:251260" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV000494627" DateUpdated="2022-10-01" DateCreated="2016-07-01" Type="SCV" Version="2" SubmitterName="GeneReviews" OrgID="500062" OrganizationCategory="resource" OrgAbbreviation="GeneReviews" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16033915</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">14973119</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15185344</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19908051</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20444919</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11953735</ID>
          </Citation>
          <Citation>
            <ID Source="BookShelf">NBK1176</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Slavic</Ethnicity>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NP_002476.2:p.Lys219AsnfsTer15</Name>
            <Name>657del5</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661del5</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0398791" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11808016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="27552" SubmissionDate="2016-10-11" DateLastUpdated="2016-07-01" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="602667.0001_NIJMEGEN BREAKAGE SYNDROME" title="NBN, 5-BP DEL, NT657_NIJMEGEN BREAKAGE SYNDROME" />
        <ClinVarAccession Accession="SCV000027552" DateUpdated="2016-07-01" DateCreated="2013-04-04" Type="SCV" Version="4" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2008-10-15">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In patients of Slavic origin with Nijmegen breakage syndrome (NBS; 251260), Varon et al. (1998) identified a common deletion of 5 nucleotides in exon 6 of the NBS1 gene (657del5), resulting in a frameshift and a truncated protein. A total of 46 patients homozygous for this mutation were identified. The mutation was found exclusively on a specific 'Slavic' haplotype of linked polymorphic markers.</Attribute>
              <Citation>
                <ID Source="PubMed">9590180</ID>
              </Citation>
              <XRef DB="OMIM" ID="251260" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Matsuura et al. (1998) found the same 5-bp deletion in the NBS1 gene in 13 NBS patients of Slavic or German origin. Twelve patients were homozygous for the deletion and 1 was heterozygous. The deletion introduced a premature termination signal at codon 218, which was predicted to result in a severely truncated polypeptide. Matsuura et al. (1998) concluded that they had identified the gene involved in NBS because complementation was effected by a YAC that contained the gene and because no (or extremely reduced) expression of the gene was found in a patient without the deletion but with the NBS phenotype. The presence of a founder mutation in 13 of 14 cases, with no demonstration of the deletion in 50 normal individuals of the same ethnic origin or in 7 normal chromosomes from NBS parents, supported this conclusion.</Attribute>
              <Citation>
                <ID Source="PubMed">9620777</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">The truncating 657del5 had been identified in 90% of NBS patients. NBS shares a number of features with ataxia-telangiectasia (208900), the most notable being high sensitivity to ionizing radiation and predisposition to cancer. Patients who are heterozygous for the ATM mutation are predisposed to breast cancer. Since the NBS phenotype at the cellular level is very similar to that of ataxia-telangiectasia, Carlomagno et al. (1999) screened 477 German breast cancer patients, aged under 51 years, and 866 matched controls for the common NBS mutation. They identified 1 carrier among the cases and 1 among the controls, indicating that the population frequency of this NBS mutation is 1 in 866 persons (95% CI = 1 in 34,376 to 1 in 156) and the estimated prevalence of NBS is thus 1 in 3 million persons. The proportion of breast cancer attributable to this mutation is less than 1%.</Attribute>
              <Citation>
                <ID Source="PubMed">10398434</ID>
              </Citation>
              <XRef DB="OMIM" ID="208900" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Kleier et al. (2000) reported a 5-year-old Bosnian boy with severe microcephaly. Because of multiple structural aberrations involving chromosomes 7 and 14 typical for ataxia-telangiectasia, that disorder was diagnosed. However, the diagnosis of NBS was suggested by the boy's remarkable microcephaly, his facial appearance, and the absence of ataxia and telangiectasia. DNA analysis demonstrated homozygosity for the major mutation in the NBS1 gene, 657del5.</Attribute>
              <Citation>
                <ID Source="PubMed">10852373</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Maser et al. (2001) tested the hypothesis that the NBS1 657del5 mutation is a hypomorphic defect. They showed that NBS cells harboring the 657del5 mutation contained a predicted 26-kD N-terminal protein, NBS1(p26), and a 70-kD NBS1 protein, NBS1(p70), lacking the native N terminus. The 26-kD protein is not physically associated with the MRE11 complex (600814), whereas the 70-kD species is physically associated with it. NBS1(p70) is produced by internal translation initiation within the NBS mRNA using an open reading frame generated by the 657del5 frameshift. Maser et al. (2001) proposed that the common NBS1 allele encodes a partially functional protein that diminishes the severity of the NBS phenotype.</Attribute>
              <Citation>
                <ID Source="PubMed">11279524</ID>
              </Citation>
              <XRef DB="OMIM" ID="600814" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Tekin et al. (2002) reported a consanguineous Turkish family whose first son died of anal atresia and whose second son, the proband, presented with severe pre- and postnatal growth retardation as well as striking microcephaly, immunodeficiency, congenital heart disease, chromosome instability, and rhabdomyosarcoma in the anal region. The patient was homozygous for the 657del5 mutation in the NBS1 gene, which is responsible for NBS in most Slavic populations. The family was the first diagnosed with NBS in the Turkish population and was one of the most severely affected examples of the syndrome.</Attribute>
              <Citation>
                <ID Source="PubMed">12123493</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Drabek et al. (2002) presented PCR with sequence specific primers as a method for detection of the 657del5 mutation. They confirmed a high carrier frequency in the Czech population (1 in 106 persons; 95% CI = 1 in 331 to 1 in 46).</Attribute>
              <Citation>
                <ID Source="PubMed">12505263</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In Russian children, Resnick et al. (2003) screened for the 657del5 NBS1 mutation in 548 controls and 68 patients with lymphoid malignancies. No carrier of the mutation was found in the control group. The mutation was found in heterozygous form in 2 of the 68 patients from the group of lymphoid malignancies, 1 with acute lymphoblastic leukemia (see 159555) and 1 with non-Hodgkin lymphoma (605027). Several relatives of the patient with non-Hodgkin lymphoma who carried the same mutation had cancer (acute lymphoblastic leukemia, breast cancer, gastrointestinal cancers), suggesting that heterozygosity may predispose to malignant disorders.</Attribute>
              <Citation>
                <ID Source="PubMed">12833396</ID>
              </Citation>
              <XRef DB="OMIM" ID="159555" Type="MIM" />
              <XRef DB="OMIM" ID="605027" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In monozygotic twin brothers with a severe form of NBS without chromosomal instability, Seemanova et al. (2006) identified compound heterozygosity for the 657del5 mutation and a 643C-T transition in exon 6 of the NBS1 gene, resulting in an arg215-to-trp (R215W) substitution (602667.0009). Both infants showed reduced expression of full-length nibrin, and radiation response processes were strongly reduced in their cells. Their mother and father were heterozygous for the 657del5 mutation and the R215W mutation, respectively, as were their respective grandfathers.</Attribute>
              <Citation>
                <ID Source="PubMed">16033915</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In a 3-month-old boy with NBS, Varon et al. (2007) identified homozygosity for the 657del5 mutation; the patient's mother carried the mutation, whereas his father was homozygous for the wildtype allele. Analysis of 27 microsatellite markers covering all of chromosome 8 revealed that the patient had a homozygous haplotype for all of the markers, whereas the mother carried the same haplotype in heterozygous state. The authors stated that this was the first patient with NBS due to maternal isodisomy of chromosome 8.</Attribute>
              <Citation>
                <ID Source="PubMed">17103455</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Porhanova et al. (2008) reported a 52-year-old Russian woman with ovarian cancer (see 604370) who was found to be compound heterozygous for a mutation in the BRCA1 gene (113705.0018) and the common Slavic 657del5 mutation in the NBN gene. Investigation of the ovarian cancer tissue showed somatic loss of heterozygosity for NBN, but retention of heterozygosity for BRCA1. The patient did not have a particularly severe cancer-prone phenotype, and her parents did not have cancer, although 3 sibs developed cancer as adults. Porhanova et al. (2008) commented that haploinsufficiency of the BRCA1 gene may contribute to cancer progression without somatic changes.</Attribute>
              <Citation>
                <ID Source="PubMed">18940477</ID>
              </Citation>
              <XRef DB="OMIM" ID="604370" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <Name>NBN, 5-BP DEL, NT657</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">5-BP DEL, NT657</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="602667.0001" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">NIJMEGEN BREAKAGE SYNDROME</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="27553" SubmissionDate="2016-10-11" DateLastUpdated="2016-10-14" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="602667.0001_OVARIAN CANCER, SUSCEPTIBILITY TO" title="NBN, 5-BP DEL, NT657_OVARIAN CANCER, SUSCEPTIBILITY TO" />
        <ClinVarAccession Accession="SCV000027553" DateUpdated="2016-10-14" DateCreated="2013-04-04" Type="SCV" Version="4" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2008-10-15">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>risk factor</GermlineClassification>
        </Classification>
        <Assertion>variation to included disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In patients of Slavic origin with Nijmegen breakage syndrome (NBS; 251260), Varon et al. (1998) identified a common deletion of 5 nucleotides in exon 6 of the NBS1 gene (657del5), resulting in a frameshift and a truncated protein. A total of 46 patients homozygous for this mutation were identified. The mutation was found exclusively on a specific 'Slavic' haplotype of linked polymorphic markers.</Attribute>
              <Citation>
                <ID Source="PubMed">9590180</ID>
              </Citation>
              <XRef DB="OMIM" ID="251260" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Matsuura et al. (1998) found the same 5-bp deletion in the NBS1 gene in 13 NBS patients of Slavic or German origin. Twelve patients were homozygous for the deletion and 1 was heterozygous. The deletion introduced a premature termination signal at codon 218, which was predicted to result in a severely truncated polypeptide. Matsuura et al. (1998) concluded that they had identified the gene involved in NBS because complementation was effected by a YAC that contained the gene and because no (or extremely reduced) expression of the gene was found in a patient without the deletion but with the NBS phenotype. The presence of a founder mutation in 13 of 14 cases, with no demonstration of the deletion in 50 normal individuals of the same ethnic origin or in 7 normal chromosomes from NBS parents, supported this conclusion.</Attribute>
              <Citation>
                <ID Source="PubMed">9620777</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">The truncating 657del5 had been identified in 90% of NBS patients. NBS shares a number of features with ataxia-telangiectasia (208900), the most notable being high sensitivity to ionizing radiation and predisposition to cancer. Patients who are heterozygous for the ATM mutation are predisposed to breast cancer. Since the NBS phenotype at the cellular level is very similar to that of ataxia-telangiectasia, Carlomagno et al. (1999) screened 477 German breast cancer patients, aged under 51 years, and 866 matched controls for the common NBS mutation. They identified 1 carrier among the cases and 1 among the controls, indicating that the population frequency of this NBS mutation is 1 in 866 persons (95% CI = 1 in 34,376 to 1 in 156) and the estimated prevalence of NBS is thus 1 in 3 million persons. The proportion of breast cancer attributable to this mutation is less than 1%.</Attribute>
              <Citation>
                <ID Source="PubMed">10398434</ID>
              </Citation>
              <XRef DB="OMIM" ID="208900" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Kleier et al. (2000) reported a 5-year-old Bosnian boy with severe microcephaly. Because of multiple structural aberrations involving chromosomes 7 and 14 typical for ataxia-telangiectasia, that disorder was diagnosed. However, the diagnosis of NBS was suggested by the boy's remarkable microcephaly, his facial appearance, and the absence of ataxia and telangiectasia. DNA analysis demonstrated homozygosity for the major mutation in the NBS1 gene, 657del5.</Attribute>
              <Citation>
                <ID Source="PubMed">10852373</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Maser et al. (2001) tested the hypothesis that the NBS1 657del5 mutation is a hypomorphic defect. They showed that NBS cells harboring the 657del5 mutation contained a predicted 26-kD N-terminal protein, NBS1(p26), and a 70-kD NBS1 protein, NBS1(p70), lacking the native N terminus. The 26-kD protein is not physically associated with the MRE11 complex (600814), whereas the 70-kD species is physically associated with it. NBS1(p70) is produced by internal translation initiation within the NBS mRNA using an open reading frame generated by the 657del5 frameshift. Maser et al. (2001) proposed that the common NBS1 allele encodes a partially functional protein that diminishes the severity of the NBS phenotype.</Attribute>
              <Citation>
                <ID Source="PubMed">11279524</ID>
              </Citation>
              <XRef DB="OMIM" ID="600814" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Tekin et al. (2002) reported a consanguineous Turkish family whose first son died of anal atresia and whose second son, the proband, presented with severe pre- and postnatal growth retardation as well as striking microcephaly, immunodeficiency, congenital heart disease, chromosome instability, and rhabdomyosarcoma in the anal region. The patient was homozygous for the 657del5 mutation in the NBS1 gene, which is responsible for NBS in most Slavic populations. The family was the first diagnosed with NBS in the Turkish population and was one of the most severely affected examples of the syndrome.</Attribute>
              <Citation>
                <ID Source="PubMed">12123493</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Drabek et al. (2002) presented PCR with sequence specific primers as a method for detection of the 657del5 mutation. They confirmed a high carrier frequency in the Czech population (1 in 106 persons; 95% CI = 1 in 331 to 1 in 46).</Attribute>
              <Citation>
                <ID Source="PubMed">12505263</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In Russian children, Resnick et al. (2003) screened for the 657del5 NBS1 mutation in 548 controls and 68 patients with lymphoid malignancies. No carrier of the mutation was found in the control group. The mutation was found in heterozygous form in 2 of the 68 patients from the group of lymphoid malignancies, 1 with acute lymphoblastic leukemia (see 159555) and 1 with non-Hodgkin lymphoma (605027). Several relatives of the patient with non-Hodgkin lymphoma who carried the same mutation had cancer (acute lymphoblastic leukemia, breast cancer, gastrointestinal cancers), suggesting that heterozygosity may predispose to malignant disorders.</Attribute>
              <Citation>
                <ID Source="PubMed">12833396</ID>
              </Citation>
              <XRef DB="OMIM" ID="159555" Type="MIM" />
              <XRef DB="OMIM" ID="605027" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In monozygotic twin brothers with a severe form of NBS without chromosomal instability, Seemanova et al. (2006) identified compound heterozygosity for the 657del5 mutation and a 643C-T transition in exon 6 of the NBS1 gene, resulting in an arg215-to-trp (R215W) substitution (602667.0009). Both infants showed reduced expression of full-length nibrin, and radiation response processes were strongly reduced in their cells. Their mother and father were heterozygous for the 657del5 mutation and the R215W mutation, respectively, as were their respective grandfathers.</Attribute>
              <Citation>
                <ID Source="PubMed">16033915</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In a 3-month-old boy with NBS, Varon et al. (2007) identified homozygosity for the 657del5 mutation; the patient's mother carried the mutation, whereas his father was homozygous for the wildtype allele. Analysis of 27 microsatellite markers covering all of chromosome 8 revealed that the patient had a homozygous haplotype for all of the markers, whereas the mother carried the same haplotype in heterozygous state. The authors stated that this was the first patient with NBS due to maternal isodisomy of chromosome 8.</Attribute>
              <Citation>
                <ID Source="PubMed">17103455</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Porhanova et al. (2008) reported a 52-year-old Russian woman with ovarian cancer (see 604370) who was found to be compound heterozygous for a mutation in the BRCA1 gene (113705.0018) and the common Slavic 657del5 mutation in the NBN gene. Investigation of the ovarian cancer tissue showed somatic loss of heterozygosity for NBN, but retention of heterozygosity for BRCA1. The patient did not have a particularly severe cancer-prone phenotype, and her parents did not have cancer, although 3 sibs developed cancer as adults. Porhanova et al. (2008) commented that haploinsufficiency of the BRCA1 gene may contribute to cancer progression without somatic changes.</Attribute>
              <Citation>
                <ID Source="PubMed">18940477</ID>
              </Citation>
              <XRef DB="OMIM" ID="604370" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <Name>NBN, 5-BP DEL, NT657</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">5-BP DEL, NT657</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="602667.0001" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="included">OVARIAN CANCER, SUSCEPTIBILITY TO</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1571399" SubmissionDate="2023-10-19" DateLastUpdated="2023-11-20" DateCreated="2018-09-13">
        <ClinVarSubmissionID localKey="913044|NBN-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000806448" DateUpdated="2023-11-20" DateCreated="2018-09-13" Type="SCV" Version="2" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-03-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The NBN c.657_661del5 variant is predicted to result in a frameshift and premature protein termination (p.Lys219Asnfs*16). The c.657_661del variant (also known as c.657del5) in the NBN gene is a founder pathogenic variant in the Slavic population and causes Nijmegen breakage syndrome in the homozygous state or in combination with another pathogenic variant in NBN (Varon et al. 1998. PubMed ID: 9590180). Functionally, it has been hypothesized to be a hypomorph, which results in a truncated protein with residual activity of the full-length NBN protein (Maser et al. 2001. PubMed ID: 11279524; Dzikiewicz-Krawczyk et al. 2011. PubMed ID: 22131123). However, this variant has been reported in up to ~0.04% of individuals (primarily within Europeans) in a large population database of presumably healthy individuals (http://gnomad.broadinstitute.org/variant/8-90983441-ATTTGT-A). In ClinVar, this variant has been classified as pathogenic as well as a risk factor (https://www.ncbi.nlm.nih.gov/clinvar/variation/6940/). Frameshift variants in NBN are expected to be pathogenic. This variant is interpreted as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661del5</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">NBN-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13915440</SubmissionName>
          <SubmissionName>SUB3589995</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3961838" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2021-11-29">
        <ClinVarSubmissionID localKey="a700545f84d5d1c1209ff315e912479bdbc7a176e537a37ca0f017976cb327b5|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002018221" DateUpdated="2024-02-04" DateCreated="2021-11-29" Type="SCV" Version="3" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" OrgAbbreviation="PKIG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-06-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10694847</SubmissionName>
          <SubmissionName>SUB12926214</SubmissionName>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="395496" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2015-03-29">
        <ClinVarSubmissionID localKey="17303|MedGen:C0398791" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000218835" DateUpdated="2024-02-20" DateCreated="2015-03-29" Type="SCV" Version="14" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">14973119</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15185344</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18606567</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19908051</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24113799</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9590180</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16033915</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22131123</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22941933</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Lys219Asnfs*16) in the NBN gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 536 amino acid(s) of the NBN protein. This variant is present in population databases (rs587776650, gnomAD 0.04%). This premature translational stop signal has been observed in individual(s) with NBN-related conditions (PMID: 14973119, 15185344, 18606567, 19908051, 24113799). It is commonly reported in individuals of Slavic ancestry (PMID: 9590180). This variant is also known as 657del5. ClinVar contains an entry for this variant (Variation ID: 6940). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects NBN function (PMID: 16033915, 22131123, 22941933). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000008.10:g.90983442_90983446del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0398791" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200279</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1329200" SubmissionDate="2017-06-22" DateLastUpdated="2018-01-06" DateCreated="2018-01-06">
        <ClinVarSubmissionID localKey="569|OMIM:251260" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000678042" DateUpdated="2018-01-06" DateCreated="2018-01-06" Type="SCV" Version="1" SubmitterName="Counsyl" OrgID="320494" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-06-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">22941933</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16544999</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19635536</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22293976</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11953735</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9590180</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22131123</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Counsyl Autosomal and X-linked Recessive Disease Classification criteria (2015)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rb7nm21v/ar_xl2015criteria.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661del5</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251260" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB2805609</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1364330" SubmissionDate="2018-01-25" DateLastUpdated="2018-01-06" DateCreated="2018-01-06">
        <ClinVarSubmissionID localKey="NM_002485.4:c.657_661delACAAA|MedGen:C0398791" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000697978" DateUpdated="2018-01-06" DateCreated="2018-01-06" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-11-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9590180</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22941933</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
            <CitationText>LabCorp Variant Classification Summary - May 2015.docx</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <XRefList>
            <XRef DB="dbSNP" ID="587776650" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661delACAAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0398791" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2016-2017-variants</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2876008" SubmissionDate="2020-12-28" DateLastUpdated="2021-01-02" DateCreated="2021-01-02">
        <ClinVarSubmissionID localKey="NM_002485.4:c.657_661delACAAA|Nijmegen breakage syndrome" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001460733" DateUpdated="2021-01-02" DateCreated="2021-01-02" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-09-16">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661delACAAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Nijmegen breakage syndrome</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8808661</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2913957" SubmissionDate="2020-12-16" DateLastUpdated="2021-06-19" DateCreated="2021-06-19">
        <ClinVarSubmissionID localKey="NM_002485.5:c.657_661delACAAA|OMIM:251260" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001478131" DateUpdated="2021-06-19" DateCreated="2021-06-19" Type="SCV" Version="1" SubmitterName="Department of Pediatrics, Memorial Sloan Kettering Cancer Center" OrgID="506177" OrganizationCategory="clinic" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-12-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">28873162</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.5:c.657_661delACAAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251260" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8689141</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2922152" SubmissionDate="2021-02-23" DateLastUpdated="2021-03-07" DateCreated="2021-03-07">
        <ClinVarSubmissionID localKey="11" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001482292" DateUpdated="2021-03-07" DateCreated="2021-03-07" Type="SCV" Version="1" SubmitterName="Department of Pediatric Oncology,  Hematology and Clinical Immunology, University Clinics Duesseldorf" OrgID="507961" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>flagged submission</ReviewStatus>
          <GermlineClassification>Uncertain significance</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>maternal</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <FamilyData>
                <FamilyHistory>no</FamilyHistory>
              </FamilyData>
              <Proband>yes</Proband>
              <Indication Type="Indication">
                <Trait Type="Disease">
                  <XRef DB="MedGen" ID="C0019829" Type="CUI" />
                </Trait>
              </Indication>
            </Sample>
            <Method>
              <TypePlatform>Next Generation Sequencing</TypePlatform>
              <MethodType>research</MethodType>
              <MethodAttribute>
                <Attribute Type="TestName">Whole-Exome sequencing</Attribute>
              </MethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000008.10:g.90983442_90983446del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <Comment DataSource="ClinGen" Type="FlaggedComment">Notes: None</Comment>
        <Comment DataSource="ClinGen" Type="FlaggedComment">Reason: Outlier claim with insufficient supporting evidence</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB9130041</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2939434" SubmissionDate="2020-12-10" DateLastUpdated="2021-03-07" DateCreated="2021-03-07">
        <ClinVarSubmissionID localKey="NM_002485.4:c.657_661delACAAA|OMIM:604370" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001499751" DateUpdated="2021-03-07" DateCreated="2021-03-07" Type="SCV" Version="1" SubmitterName="Department of Molecular Diagnostics, Institute of Oncology Ljubljana" OrgID="506646" OrganizationCategory="laboratory" OrgAbbreviation="DMD-OI" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-04-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661delACAAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="604370" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8712451</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3054349" SubmissionDate="2021-03-31" DateLastUpdated="2021-04-13" DateCreated="2021-04-13">
        <ClinVarSubmissionID localKey="chr8:90983440-90983446:79f8fb9764098aa432efde18fb7415b6-BREAST" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001553205" DateUpdated="2021-04-13" DateCreated="2021-04-13" Type="SCV" Version="1" SubmitterName="Department of Pathology and Laboratory Medicine, Sinai Health System" OrgID="506152" OrganizationCategory="laboratory" OrgAbbreviation="PLM-SHS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="506759" SubmitterName="Franklin by Genoox" Type="secondary" OrganizationCategory="other" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The NBN p.Lys219Asnfs*16 variant was identified in 50 of 30494 proband chromosomes (frequency: 0.002) from individuals or families with pancreatic ductal adenocarcinoma, medulloblastoma, prostate cancer, breast cancer, ovarian cancer, non-Hodgkin lymphoma, or colorectal cancer and was present in 20 of 6450 control chromosomes (frequency: 0.003) from healthy individuals (Borecka 2016, Ciara 2010, Cybulski 2004, Domagala 2015, Kraus 2017, Lhota 2016, Steffen 2004, Susswein 2015, Tung 2015). This variant is a Slavic founder mutation with carrier frequency among newborns in the range of 1/154 in the Czech Republic to 1/190 in Poland (Steffen 2004). The variant was also identified in dbSNP (ID: rs587776650 as "With Pathogenic allele"), ClinVar (classified as pathogenic by Invitae, GeneDx, Ambry Genetics and twelve other submitters), and LOVD 3.0 (4x). The variant was identified in control databases in 55 of 276598 chromosomes at a frequency of 0.0002 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: European in 50 of 126360 chromosomes (freq: 0.0004), Other in 1 of 6436 chromosomes (freq: 0.0002), Finnish in 2 of 25738 chromosomes (freq: 0.00008), and Latino in 2 of 34324 chromosomes (freq: 0.00006); it was not observed in the African, Ashkenazi Jewish, East Asian, or South Asian populations. Functional studies have reported that the variant leads to two truncated fragments, p26 and p70 nibrin, and the translation of a short N-terminal protein with FHA/BRCT domains, therefore maintaining some function of the full-length NBS1 protein (Dzikiewicz-Krawczyk 2008, Cilli 2014). The variant has been associated with an increased risk of breast cancer and medulloblastoma, and a significant increase in overall cancer risks (Zhang 2013, Ciara 2010, Gao 2013, Borecka 2016). The c.657_661del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 219 and leads to a premature stop codon at position 234. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the NBN gene are an established mechanism of disease in NBN-associated cancer and is the type of variant expected to cause the disorder. In summary, based on the above information, this variant meets our laboratoryâ€šÃ„Ã´s criteria to be classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="8" alternateAllele="A" referenceAllele="ATTTGT" start="90983441" stop="90983446" variantLength="6" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0007254" />
          </Trait>
        </TraitSet>
        <StudyName>The Canadian Open Genetics Repository (COGR)</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB9371647</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3533851" SubmissionDate="2021-08-20" DateLastUpdated="2021-08-21" DateCreated="2021-08-21">
        <ClinVarSubmissionID localKey="SUB10228191" submittedAssembly="GRCh37" title="SUB10228191" />
        <ClinVarAccession Accession="SCV001797297" DateUpdated="2021-08-21" DateCreated="2021-08-21" Type="SCV" Version="1" SubmitterName="Medical Genetics Laboratory, Umraniye Training and Research Hospital, University of Health Sciences" OrgID="508187" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-08-20">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Invasive Ductal Carcinoma Estrogen Receptor: Positive Progesterone Receptor: Positive HER2 Receptor: Positive</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">60</Age>
              <Age Type="maximum" age_unit="years">69</Age>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN">
              <Name>nibrin</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="HP" ID="HP:0003002" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10228191</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4953884" SubmissionDate="2022-04-25" DateLastUpdated="2022-06-24" DateCreated="2022-06-24">
        <ClinVarSubmissionID localKey="NM_002485.4:c.657_661delACAAA|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002536702" DateUpdated="2022-06-24" DateCreated="2022-06-24" Type="SCV" Version="1" SubmitterName="Sema4, Sema4" OrgID="500057" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-05-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">22373003</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24113799</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27150568</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11279524</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22131123</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30426508</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29368341</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23317186</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9590180</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Sema4 Curation Guidelines</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/cy0kpury/sema4_variant_curation_guidelines-clinvar_april_2022.docx</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661delACAAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <Comment>The NBN c.657_661del (p.Lys219Asnfs*16, also known as 657del5) variant has been associated with increased risk for NBN-related cancers. This variant has been observed in multiple ethnic backgrounds with highest frequencies in individuals of European non-Finnish ancestry (0.040%, the Genome Aggregation Database (gnomAD); PMID:32461654). This variant is also present in the ClinVar database (ID: 6940). Additionally, in the bi-allelic state, this variant is the most common variant associated with autosomal recessive Nijmegen Breakage Syndrome (NBS) (PMID:22373003). A meta-analysis has reported an increased risk of developing cancer in the Caucasian population (OR=2.79 [95% CI 2.17-3.68] PMID:24113799). The stratified analysis from this same study reported significant odds ratios in carriers of the variant for multiple cancers, particularly breast cancer (OR = 2.51 [95% CI=1.68-3.73]), prostate cancer (OR = 5.87 [95% CI=2.51-13.75]), and lymphoma (OR = 2.93 [95% CI=1.62-5.29]). Additionally, a case control study has reported an association between this variant and pancreatic ductal adenocarcinoma in Czechs of Slavic descent (OR = 9.7 [95% CI= 1.9-50.2] PMID:27150568). This variant is predicted to cause a frameshift at amino acid 219 that results in premature termination 16 amino acids downstream which is a candidate for nonsense-mediated decay (NMD) leading to absent protein (loss of function). However, it has been shown that the mRNA escapes NMD via reinitiating translation and results in an N-terminally truncated NBN protein that leads to a partially functional protein (PMID: 11279524). Additional in vitro functional studies support an impact on protein function (PMID:22131123) and loss of function of the NBN gene is an established disease mechanism in autosomal recessive NBS. In summary, this variant is not expected to cause highly penetrant Mendelian disease in the heterozygous form but is an established risk allele and is classified as pathogenic with low penetrance for the development of breast, prostate, and lymphoid cancers.</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB11360768</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5022287" SubmissionDate="2022-07-12" DateLastUpdated="2022-09-03" DateCreated="2022-09-03">
        <ClinVarSubmissionID localKey="53611385|OMIM:251260" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002568311" DateUpdated="2022-09-03" DateCreated="2022-09-03" Type="SCV" Version="1" SubmitterName="Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center" OrgID="1019" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>PVS1, PS3, PM3</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251260" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11782039</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5031038" SubmissionDate="2022-09-02" DateLastUpdated="2022-09-17" DateCreated="2022-09-17">
        <ClinVarSubmissionID localKey="NM_002485.5:c.657_661del|OMIM:251260" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV002573431" DateUpdated="2022-09-17" DateCreated="2022-09-17" Type="SCV" Version="1" SubmitterName="Clinic of Clinical Immunology with Stem Cell Bank, Expert Centre for Rare Diseases - PID, University Hospital &quot;Alexandrovska&quot;" OrgID="508564" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.5:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251260" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11917960</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3417654" SubmissionDate="2022-10-07" DateLastUpdated="2022-10-22" DateCreated="2021-06-19">
        <ClinVarSubmissionID localKey="NM_002485.4:c.657_661del|OMIM:251260" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001737447" DateUpdated="2022-10-22" DateCreated="2021-06-19" Type="SCV" Version="3" SubmitterName="St. Jude Molecular Pathology, St. Jude Children's Research Hospital" OrgID="506672" OrganizationCategory="laboratory" OrgAbbreviation="SJCRH-MP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-09-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The NBN c.657_661del (p.Lys219fs) change deletes five nucleotides and causes a frameshift and the creation of a premature stop codon. This change is predicted to cause protein truncation or absence of the protein due to nonsense mediated decay. This variant has a maximum subpopulation frequency of 0.040% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). This is the most common pathogenic variant reported in individuals affected with Nijmegen breakage syndrome (PMID: 9590180, 20301355). In addition, this variant has been identified as heterozygous in individuals with many cancer types including breast, lymphoma, prostate, melanoma, medulloblastoma, and others (PMID: 15185344, 14973119, 18606567, 19908051, 24113799). Case-control studies have demonstrated evidence of association with breast cancer (OR = 2.63), prostate cancer (OR = 5.87), and lymphoma (OR = 2.93) (PMID: 23317186, 24113799). This variant is present 5x in the FLOSSIES database which contains genetic variants from women older than 70 years of age who have never had cancer (https://whi.color.com/). In summary, this variant meets criteria to be classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">St. Jude Assertion Criteria 2020</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/0uggzi4w/st._jude_assertion_criteria_2020.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251260" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12131575</SubmissionName>
          <SubmissionName>SUB9886457</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1610880" SubmissionDate="2018-08-20" DateLastUpdated="2022-12-11" DateCreated="2018-10-10">
        <ClinVarSubmissionID localKey="NC_000008.10:g.90983442_90983446delTTTGT|MedGen:C0398791" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000838310" DateUpdated="2022-12-11" DateCreated="2018-10-10" Type="SCV" Version="2" SubmitterName="Mendelics" OrgID="500035" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-07-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Mendelics Assertion Criteria 2017</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/chhjzatu/mendelics_assertion_criteria_2017.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000008.10:g.90983442_90983446delTTTGT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Microcephaly, normal intelligence and immunodeficiency</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0398791" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB4427121</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="270367" SubmissionDate="2021-11-17" DateLastUpdated="2023-03-04" DateCreated="2014-05-14">
        <ClinVarSubmissionID localKey="GDXSV:214091" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV000149712" DateUpdated="2023-03-04" DateCreated="2014-05-14" Type="SCV" Version="16" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Case control studies suggest this variant is associated with prostate cancer; earlier studies also describe associated risk for breast cancer and lymphoma, though additional studies have not been supportive (Zhang 2012, Cybulski 2013, Gao 2013, Rogoa-Janiszewska 2020, Wokoorczyk 2020, Hu 2021); Also known as 657del5; This variant is associated with the following publications: (PMID: 9590180, 19908051, 23317186, 32255556, 18073374, 24619942, 26929905, 28649662, 29785153, 30426508, 30322717, 30612635, 22131123, 22293976, 25485873, 23765759, 16770759, 23149842, 22941933, 19635536, 14973119, 19452044, 16033915, 27150568, 27038244, 19393249, 27276934, 26083025, 26822949, 25980754, 27616075, 28008555, 26681312, 28374160, 28873162, 28376765, 25186627, 15185344, 11093281, 18606567, 11279524, 16544999, 11953735, 18940477, 12833396, 12505263, 12123493, 10852373, 10398434, 9620777, 29368341, 29915322, 29555771, 29753700, 28152038, 26265251, 31173646, 30590007, 31187634, 31159747, 29419426, 31980526, 33178177, 31589614, 32338768, 33488600, 32441320, 32843899, 24113799, 33077847, 32427313)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:43729</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_71_20211117054204</SubmissionName>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3923914" SubmissionDate="2023-07-12" DateLastUpdated="2023-07-16" DateCreated="2021-10-30">
        <ClinVarSubmissionID localKey="Chr.8_89971213_89971218_ATTTGT_A|not provided" />
        <ClinVarAccession Accession="SCV002010433" DateUpdated="2023-07-16" DateCreated="2021-10-30" Type="SCV" Version="3" SubmitterName="Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden" OrgID="505632" OrganizationCategory="clinic" OrgAbbreviation="KGE" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh38" Chr="8" alternateAllele="A" referenceAllele="ATTTGT" start="89971213" stop="89971218" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10612882</SubmissionName>
          <SubmissionName>SUB13603663</SubmissionName>
          <SubmissionName>SUB13676335</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7535882" SubmissionDate="2023-09-04" DateLastUpdated="2023-08-26" DateCreated="2023-08-26">
        <ClinVarSubmissionID localKey="4087958_NM_002485.5:c.657_661del|OMIM:251260" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004027783" DateUpdated="2023-08-26" DateCreated="2023-08-26" Type="SCV" Version="1" SubmitterName="Institute of Human Genetics, University of Leipzig Medical Center" OrgID="506086" OrganizationCategory="clinic" OrgAbbreviation="UKL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Criteria applied: PVS1,PS3,PS4,PM2_SUP</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>maternal</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>male</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0032317" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.5:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251260" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13762194</SubmissionName>
          <SubmissionName>SUB13814879</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1739442" SubmissionDate="2023-12-22" DateLastUpdated="2024-01-06" DateCreated="2018-09-13">
        <ClinVarSubmissionID localKey="S294|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000889554" DateUpdated="2024-01-06" DateCreated="2018-09-13" Type="SCV" Version="4" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" OrgAbbreviation="Quest Diagnostics" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-08-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11279524</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15185344</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">14973119</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18606567</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19908051</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24113799</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9590180</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25485873</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22131123</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22941933</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15279809</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25980754</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26083025</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33471974</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26822949</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27616075</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29368341</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30426508</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31173646</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33471991</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33840814</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">34544220</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">34072659</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33050356</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">34072463</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">35309086</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12845677</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22491912</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10848790</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23317186</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9590181</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27150568</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29419426</ID>
          </Citation>
          <Comment>This frameshift variant alters the translational reading frame of the NBN mRNA and causes the premature termination of NBN protein synthesis. Functional studies have shown that this variant results in two proteins, the N-terminal p26 fragment and the p70 fragment produced from an internal initiation codon at position p.221 that lacks the N-terminal portion (PMID: 11279524 (2001), 25485873 (2014)). Another study has shown that the variant caused increased chromosomal instability in homozygous cells (PMID: 22131123 (2012)). The frequency of this variant in the general population, 0.00041 (21/50678 chromosomes, http://gnomad.broadinstitute.org), is consistent with pathogenicity. The c.657_661del variant is the most common pathogenic variant found in individuals affected by Nijmegen breakage syndrome (NBS) (PMID: 9590180 (1998), 20301355 (2017)). In the published literature, previous studies showed an association to breast cancer (PMID: 12845677 (2003), 22491912 (2012), 23317186 (2012)), however, recent studies do not support this association (PMID: 34072463 (2021), 33471974 (2021), 33471991 (2021)). The variant is also reported to have an increased risk overall for cancer (PMID: 24113799 (2013), 15185344 (2004)), including pancreatic cancer (PMID: 27150568 (2016), 35309086 (2022)), prostate cancer (PMID: 14973119 (2004)), medulloblastoma (PMID: 19908051 (2010)), and relapse of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) (PMID: 29419426 (2018)). Based on the available information, this variant is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Quest Diagnostics criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12490872</SubmissionName>
          <SubmissionName>SUB14108248</SubmissionName>
          <SubmissionName>SUB4481696</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2284684" SubmissionDate="2024-01-24" DateLastUpdated="2024-02-20" DateCreated="2020-02-10">
        <ClinVarSubmissionID localKey="2207620|MedGen:CN235283" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001160103" DateUpdated="2024-02-20" DateCreated="2020-02-10" Type="SCV" Version="3" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The NBN c.657_661del; p.Lys219AsnfsTer16 variant (rs587776650), also known as 657del5, is reported in the literature as the most common pathogenic variant and a founder mutation in the Slavic population in individuals affected with Nijmegen breakage syndrome (Varon 1998). Heterozygous carriers are also reported to have an increased risk for various cancers, including breast cancer, prostate cancer, colorectal cancer, lymphoma, melanoma, and medulloblastoma (Ciara 2010, Gao 2013, Steffen 2004). However, more recent large, multi-ethnic case control studies have demonstrated that heterozygous pathogenic NBN variants are not associated with an increased risk for breast cancer (Breast Cancer Association Consortium 2021, Hu 2021). Data regarding other cancer risks remains inconclusive. This variant is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 6940), and is found in the non-Finnish European population with an allele frequency of 0.040% (52/128,774 alleles) in the Genome Aggregation Database. This variant causes a frameshift by deleting 5 nucleotides, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. However, functional studies show two in-frame start codons created by the frameshift that can generate truncated NBN proteins with partial functionality (Lins 2009, Maser 2001). Based on available information, the p.Lys219AsnfsTer16 variant is considered to be pathogenic. References: Breast Cancer Association Consortium, Dorling L, Carvalho S, et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021;384(5):428-439. PMID: 33471991 Ciara E et al. Heterozygous germ-line mutations in the NBN gene predispose to medulloblastoma in pediatric patients. Acta Neuropathol. 2010 Mar;119(3):325-34. PMID: 19908051. Gao P et al. Functional variants in NBS1 and cancer risk: evidence from a meta-analysis of 60 publications with 111 individual studies. Mutagenesis. 2013 Nov;28(6):683-97. PMID: 24113799. Hu C et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med. 2021;384(5):440-451. PMID: 33471974 Lins S et al. Clinical variability and expression of the NBN c.657del5 allele in Nijmegen Breakage Syndrome. Gene. 2009 Nov 1;447(1):12-7. PMID: 19635536. Maser RS et al. An alternative mode of translation permits production of a variant NBS1 protein from the common Nijmegen breakage syndrome allele. Nat Genet. 2001 Apr;27(4):417-21. PMID: 11279524. Steffen J et al. Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int J Cancer. 2004 Aug 10;111(1):67-71. PMID: 15185344. Varon R et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell. 1998 May 1;93(3):467-76. PMID: 9590180.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process 2024</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/xwiqgyug/arup_molecular_germline_variant_investigation_process_arup-info-0022_2024.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000008.10:g.90983445_90983449del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN235283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2020 ARUP</SubmissionName>
          <SubmissionName>2023 ARUP ClinVar submission</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="302307" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2014-08-06">
        <ClinVarSubmissionID localKey="a4132|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000183792" DateUpdated="2024-05-01" DateCreated="2014-08-06" Type="SCV" Version="8" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-08-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10799436</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10852373</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11093281</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11279524</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">14973119</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15185344</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19908051</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22293976</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26083025</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26822949</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27150568</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9620777</ID>
          </Citation>
          <Comment>The c.657_661delACAAA pathogenic mutation, located in coding exon 6 of the NBN gene, results from a deletion of 5 nucleotides at positions 657 to 661, causing a translational frameshift with a predicted alternate stop codon (p.K219Nfs*16). The c.657_661delACAAA mutation (commonly referred to as 657del5 in the literature) is the most common NBN mutation in Eastern European individuals with Nijmegen Breakage Syndrome (Varon R et al. Eur. J. Hum. Genet., 2000 Nov;8:900-2). This mutation has been reported with increased frequency in individuals with medulloblastoma, prostate cancer, pancreatic cancer, melanoma, breast cancer, colon cancer, and non-Hodgkin's lymphoma (Borecka M et al. Gene, 2016 Aug;587:169-72; Ciara E et al. Acta Neuropathol., 2010 Mar;119:325-34; Cybulski C et al. Cancer Res., 2004 Feb;64:1215-9; Domagala P et al. PLoS ONE, 2015 Jun;10:e0130393; Kraus C et al. Int. J. Cancer. 2017 Jan;140:95-102; Lhota F et al. Clin. Genet., 2016 Oct;90:324-33; Steffen J et al. Int. J. Cancer, 2004 Aug;111:67-71). This variant has also been observed, in the homozyous and compound heterozygous state, in patients with Nijmegen Breakage syndrome (Matsuura S et al. Nat Genet, 1998 Jun;19:179-81; Kleier S et al. Clin Genet, 2000 May;57:384-7; Szczauba K et al. J. Appl. Genet., 2012 May;53:189-91). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. However, functional studies have indicated that this alteration may partially escape nonsense-mediated decay and produce a protein with some residual function (Maser RS et al. Nat Genet, 2001 Apr;27:417-21). Based on the supporting clinical evidence, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661delACAAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
          <SubmissionName>NonExomeUpdate_081220AmbryReport</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9810920" SubmissionDate="2024-06-11" DateLastUpdated="2024-06-17" DateCreated="2024-06-17">
        <ClinVarSubmissionID localKey="NM_002485.5:c.657_661del|OMIM:251260" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV005051878" DateUpdated="2024-06-17" DateCreated="2024-06-17" Type="SCV" Version="1" SubmitterName="Laboratory of Medical Genetics, National &amp; Kapodistrian University of Athens" OrgID="506664" OrganizationCategory="laboratory" OrgAbbreviation="LMG-NKUA" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.5:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251260" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14526024</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7843761" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_002485.5:c.657_661del|OMIM:609135" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004199484" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-03-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.5:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="609135" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3442557" SubmissionDate="2021-04-26" DateLastUpdated="2024-06-17" DateCreated="2021-07-18">
        <ClinVarSubmissionID localKey="nvtapin_16784" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001749450" DateUpdated="2024-06-17" DateCreated="2021-07-18" Type="SCV" Version="2" SubmitterName="GenomeConnect - Invitae Patient Insights Network" OrgID="508034" OrganizationCategory="patient registry" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Comment>Variant interpreted as Pathogenic and reported on 10-26-2020 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">30</Age>
              <Age Type="maximum" age_unit="years">39</Age>
              <AffectedStatus>unknown</AffectedStatus>
              <Gender>female</Gender>
              <Indication Type="Indication">
                <Trait Type="Finding">
                  <Name>
                    <ElementValue Type="Preferred">Presymptomatic</ElementValue>
                  </Name>
                </Trait>
              </Indication>
            </Sample>
            <Method>
              <TypePlatform>Gene Panel Sequencing</TypePlatform>
              <MethodType>phenotyping only</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="TestingLaboratory" dateValue="2020-10-26" integerValue="500031">Invitae</Attribute>
                <Comment>Pathogenic</Comment>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <TraitSet DateLastEvaluated="2020-10-24" Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001392" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001732" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001787" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002485.4:c.657_661del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0398791" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0346153" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9483450</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2467502" SubmissionDate="2024-07-04" DateLastUpdated="2024-07-15" DateCreated="2020-05-12">
        <ClinVarSubmissionID localKey="100874|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001245910" DateUpdated="2024-07-15" DateCreated="2020-05-12" Type="SCV" Version="23" SubmitterName="CeGaT Center for Human Genetics Tuebingen" OrgID="505870" OrganizationCategory="laboratory" OrgAbbreviation="CHGT" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-05-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>NBN: PVS1, PS3, PS4:Moderate</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CeGaT Center For Human Genetics Tuebingen Variant Classification Criteria Version 2</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/0ynenhfo/cegat_center_for_human_genetics_tuebingen_-_variant_classification_criteria_-_version_2.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="29" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NBN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="8" alternateAllele="A" referenceAllele="ATTTGT" start="90983441" stop="90983446" variantLength="6" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2021-07</SubmissionName>
          <SubmissionName>2021-10</SubmissionName>
          <SubmissionName>2022-01</SubmissionName>
          <SubmissionName>2022-01-corrected</SubmissionName>
          <SubmissionName>2022-04</SubmissionName>
          <SubmissionName>2022-07</SubmissionName>
          <SubmissionName>2022-08</SubmissionName>
          <SubmissionName>2022-10.3</SubmissionName>
          <SubmissionName>2023-01</SubmissionName>
          <SubmissionName>2023-04</SubmissionName>
          <SubmissionName>2023-09-add-ACMG-details</SubmissionName>
          <SubmissionName>2023-10</SubmissionName>
          <SubmissionName>2024-04</SubmissionName>
          <SubmissionName>SUB13641132</SubmissionName>
          <SubmissionName>SUB13985080</SubmissionName>
          <SubmissionName>SUB14102099</SubmissionName>
          <SubmissionName>SUB14290090</SubmissionName>
          <SubmissionName>SUB14426581</SubmissionName>
          <SubmissionName>SUB14513473</SubmissionName>
          <SubmissionName>SUB14584463</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="480833" TraitType="Finding" MappingType="XRef" MappingValue="HP:0003220" MappingRef="Human Phenotype Ontology">
        <MedGen CUI="C4551705" Name="Abnormality of chromosome stability" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5030686" TraitType="Disease" MappingType="XRef" MappingValue="251260" MappingRef="OMIM">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2866888" TraitType="Disease" MappingType="Name" MappingValue="Breast and/or ovarian cancer" MappingRef="Preferred">
        <MedGen CUI="CN221562" Name="Breast and/or ovarian cancer" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5030686" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000126" MappingRef="HP">
        <MedGen CUI="C0020295" Name="Hydronephrosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="498393" TraitType="Finding" MappingType="Name" MappingValue="breast cancer" MappingRef="Preferred">
        <MedGen CUI="C0006142" Name="Malignant tumor of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9810920" TraitType="Disease" MappingType="XRef" MappingValue="251260" MappingRef="OMIM">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2693817" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA647" MappingRef="Orphanet">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1364330" TraitType="Disease" MappingType="XRef" MappingValue="C0398791" MappingRef="MedGen">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="962427" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000252" MappingRef="HP">
        <MedGen CUI="C4551563" Name="Microcephaly" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2693660" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2922152" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5022287" TraitType="Disease" MappingType="XRef" MappingValue="251260" MappingRef="OMIM">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5030686" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000252" MappingRef="HP">
        <MedGen CUI="C4551563" Name="Microcephaly" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="302307" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3923914" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="967778" TraitType="Disease" MappingType="XRef" MappingValue="C0398791" MappingRef="MedGen">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5024075" TraitType="Disease" MappingType="XRef" MappingValue="114550" MappingRef="OMIM">
        <MedGen CUI="C2239176" Name="Hepatocellular carcinoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3134890" TraitType="Disease" MappingType="XRef" MappingValue="C0235974" MappingRef="MedGen">
        <MedGen CUI="C0235974" Name="Carcinoma of pancreas" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="498393" TraitType="Finding" MappingType="Name" MappingValue="ovarian cancer" MappingRef="Preferred">
        <MedGen CUI="C1140680" Name="Ovarian cancer" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="395496" TraitType="Disease" MappingType="XRef" MappingValue="C0398791" MappingRef="MedGen">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3442557" TraitType="Disease" MappingType="XRef" MappingValue="C0398791" MappingRef="MedGen">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4953884" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5030686" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001511" MappingRef="HP">
        <MedGen CUI="C0015934" Name="Fetal growth restriction" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3417654" TraitType="Disease" MappingType="XRef" MappingValue="251260" MappingRef="OMIM">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3961838" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="962427" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001339" MappingRef="HP">
        <MedGen CUI="C0266463" Name="Lissencephaly" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2939434" TraitType="Disease" MappingType="XRef" MappingValue="604370" MappingRef="OMIM">
        <MedGen CUI="C2676676" Name="Breast-ovarian cancer, familial, susceptibility to, 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1571399" TraitType="Disease" MappingType="Name" MappingValue="NBN-related condition" MappingRef="Preferred">
        <MedGen CUI="None" Name="NBN-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3442557" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001392" MappingRef="HP">
        <MedGen CUI="C4021780" Name="Abnormality of the liver" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2284684" TraitType="Disease" MappingType="XRef" MappingValue="CN235283" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3054349" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0007254" MappingRef="MONDO">
        <MedGen CUI="C0006142" Name="Malignant tumor of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="27552" TraitType="Disease" MappingType="Name" MappingValue="NIJMEGEN BREAKAGE SYNDROME" MappingRef="Preferred">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="480833" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000252" MappingRef="Human Phenotype Ontology">
        <MedGen CUI="C4551563" Name="Microcephaly" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2876008" TraitType="Disease" MappingType="Name" MappingValue="Nijmegen breakage syndrome" MappingRef="Preferred">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2861309" TraitType="Disease" MappingType="Name" MappingValue="Hereditary cancer-predisposing syndrome" MappingRef="Preferred">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3442557" TraitType="Disease" MappingType="XRef" MappingValue="C0346153" MappingRef="MedGen">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="498393" TraitType="Finding" MappingType="Name" MappingValue="endometrial cancer" MappingRef="Preferred">
        <MedGen CUI="C0007103" Name="Endometrial cancer" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="459776" TraitType="Disease" MappingType="Name" MappingValue="Nijmegen breakage syndrome" MappingRef="Preferred">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1610880" TraitType="Disease" MappingType="Name" MappingValue="Microcephaly, normal intelligence and immunodeficiency" MappingRef="Preferred">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1609811" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7535882" TraitType="Finding" MappingType="XRef" MappingValue="HP:0032317" MappingRef="HP">
        <MedGen CUI="C0260515" Name="Family history of cancer" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3442557" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001732" MappingRef="HP">
        <MedGen CUI="C4025751" Name="Abnormality of the pancreas" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="480833" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001249" MappingRef="Human Phenotype Ontology">
        <MedGen CUI="C3714756" Name="Intellectual disability" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5030686" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000750" MappingRef="HP">
        <MedGen CUI="C0454644" Name="Delayed speech and language development" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="27553" TraitType="Disease" MappingType="Name" MappingValue="OVARIAN CANCER, SUSCEPTIBILITY TO" MappingRef="Alternate">
        <MedGen CUI="C2676676" Name="Breast-ovarian cancer, familial, susceptibility to, 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2913957" TraitType="Disease" MappingType="XRef" MappingValue="251260" MappingRef="OMIM">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7843761" TraitType="Disease" MappingType="XRef" MappingValue="609135" MappingRef="OMIM">
        <MedGen CUI="C0002874" Name="Aplastic anemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2292638" TraitType="Disease" MappingType="XRef" MappingValue="251260" MappingRef="OMIM">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5031038" TraitType="Disease" MappingType="XRef" MappingValue="251260" MappingRef="OMIM">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5030686" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001629" MappingRef="HP">
        <MedGen CUI="C0018818" Name="Ventricular septal defect" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1739442" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2467502" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1329200" TraitType="Disease" MappingType="XRef" MappingValue="251260" MappingRef="OMIM">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2694238" TraitType="Disease" MappingType="XRef" MappingValue="251260" MappingRef="OMIM">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3442557" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001787" MappingRef="HP">
        <MedGen CUI="C0549629" Name="Abnormal delivery" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="270367" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="498393" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5030686" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001510" MappingRef="HP">
        <MedGen CUI="C0456070" Name="Growth delay" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4011513" TraitType="Disease" MappingType="XRef" MappingValue="251260" MappingRef="OMIM">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3533851" TraitType="Disease" MappingType="XRef" MappingValue="HP:0003002" MappingRef="HP">
        <MedGen CUI="C0678222" Name="Breast carcinoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7535882" TraitType="Disease" MappingType="XRef" MappingValue="251260" MappingRef="OMIM">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="480833" TraitType="Disease" MappingType="XRef" MappingValue="251260" MappingRef="OMIM">
        <MedGen CUI="C0398791" Name="Microcephaly, normal intelligence and immunodeficiency" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="1" DateDeleted="2020-11-19">SCV001367411</Accession>
        <Description>Updated the reporting strategy binding the interpretation to OMIM (instead of HPO)</Description>
      </SCV>
      <SCV>
        <Accession Version="1" DateDeleted="2024-04-10">SCV003921052</Accession>
        <Description>Gene not longer associated with cancer predisposition</Description>
      </SCV>
      <SCV>
        <Accession Version="1" DateDeleted="2021-05-28">SCV001528071</Accession>
        <Description>not specified</Description>
      </SCV>
      <SCV>
        <Accession Version="1" DateDeleted="2021-02-04">SCV000924010</Accession>
        <Description>not specified</Description>
      </SCV>
      <SCV>
        <Accession Version="4" DateDeleted="2023-09-30">SCV000292133</Accession>
        <Description>NBN_VCV000006940: Variant is no longer reported</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

